Newcells Biotech

Newcastle Upon Tyne, United Kingdom Founded: 2014 • Age: 12 yrs
Induced pluripotent stem cell-derived organoid models are developed for research.
Request Access

About Newcells Biotech

Newcells Biotech is a company based in Newcastle Upon Tyne (United Kingdom) founded in 2014.. Newcells Biotech has raised $14.43 million across 9 funding rounds from investors including Mercia, European Union and NVM Private Equity. Newcells Biotech offers products and services including Retinal Organoids, Kidney Nephron Models, and Lung Airway Models. Newcells Biotech operates in a competitive market with competitors including InSphero, Pandorum, Vivodyne, Adapsyn and Cellesce, among others.

  • Headquarter Newcastle Upon Tyne, United Kingdom
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Newcells Biotech Limited
  • Date of Incorporation 15 Jan, 2015
  • Jurisdiction NEWCASTLE UPON TYNE, TYNE AND WEAR, UNITED KINGDOM
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $14.43 M (USD)

    in 9 rounds

  • Latest Funding Round
    $1.47 M (USD), Series B

    Dec 05, 2024

  • Investors
    Mercia

    & 5 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Newcells Biotech

Newcells Biotech offers a comprehensive portfolio of products and services, including Retinal Organoids, Kidney Nephron Models, and Lung Airway Models. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Models for retinopathies and safety studies in drug testing

Used for toxicity and drug interaction assessments

Facilitates fibrotic disease and compound efficacy studies

People of Newcells Biotech
Headcount 10-50
Employee Profiles 9
Board Members and Advisors 1
Employee Profiles
People
Colin Brown
Chief Scientific Officer
People
Mike Nicholds
CEO
People
Simon Berry
Finance Director
People
Carolina Gándara
Principal Scientist, Head Of Retina Assay Development

Unlock access to complete

Board Members and Advisors
people
Peter Dines
Non-Executive Director

Unlock access to complete

Funding Insights of Newcells Biotech

Newcells Biotech has successfully raised a total of $14.43M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $1.47 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Series B — $1.5M
  • First Round
  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2024 Amount Series B - Newcells Biotech Valuation

investors

Feb, 2024 Amount Series B - Newcells Biotech Valuation North East Fund
Feb, 2021 Amount Series B - Newcells Biotech Valuation Mercia , Northstar Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Newcells Biotech

Newcells Biotech has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, European Union and NVM Private Equity. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage investments are made in UK companies across diverse sectors.
Founded Year Domain Location
Investment finance is provided to small and medium-sized enterprises.
Founded Year Domain Location
Regional investment funds are managed by North East Finance.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Newcells Biotech

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Newcells Biotech

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Newcells Biotech Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Newcells Biotech

Newcells Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as InSphero, Pandorum, Vivodyne, Adapsyn and Cellesce, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Cell-based assays and 3D microtissues for drug screening are developed.
domain founded_year HQ Location
Regenerative medicine and 3D tissues are developed for therapeutic uses.
domain founded_year HQ Location
Developer of AI-based platform for lab-grown human tissues
domain founded_year HQ Location
Provider of computational tools for bacterial metabolomic and genomic data analysis
domain founded_year HQ Location
Scalable processes for organoid expansion are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Newcells Biotech

Frequently Asked Questions about Newcells Biotech

When was Newcells Biotech founded?

Newcells Biotech was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Newcells Biotech located?

Newcells Biotech is headquartered in Newcastle Upon Tyne, United Kingdom.

Is Newcells Biotech a funded company?

Newcells Biotech is a funded company, having raised a total of $14.43M across 9 funding rounds to date. The company's 1st funding round was a Series B of $7.37M, raised on Sep 02, 2015.

What does Newcells Biotech do?

Newcells Biotech was founded in 2014 in Newcastle Upon Tyne, United Kingdom, within the biotechnology sector. Induced pluripotent stem cell-derived organoid models are created for research applications. Off-the-shelf products, such as neural progenitor cells and cardiomyocytes, are offered alongside custom reprogramming and differentiation services. These are provided to biopharmaceutical companies and research institutions to support drug development and scientific studies.

Who are the top competitors of Newcells Biotech?

Newcells Biotech's top competitors include InSphero, Vivodyne and Parallel Bio.

What products or services does Newcells Biotech offer?

Newcells Biotech offers Retinal Organoids, Kidney Nephron Models, and Lung Airway Models.

Who are Newcells Biotech's investors?

Newcells Biotech has 6 investors. Key investors include Mercia, European Union, NVM Private Equity, Northstar Ventures, and North East Fund.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available